Cochrane · systematic review · CD010292
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
Welsch, P, Üçeyler, N, Klose, P, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsSerotonin noradrenaline reuptake inhibitors compared with placebo for fibromyalgia ‐ studies with parallel design
Population: people with fibromyalgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Self‐reported pain relief of 50% or greater Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.09 [0.07, 0.11] | 15 studies · 6918 participants | Low Downgraded: indirectness, publication bias |
Patient Global Impression to be much or very much improved (PGIC) Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.19 [0.12, 0.26] | 6 studies · 2918 participants | Low Downgraded: indirectness, publication bias |
Self‐reported fatigue (20‐100 scale) Higher scores indicate higher fatigue problem levels Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 12 studies · 6168 participants | Low Downgraded: indirectness, publication bias |
Self‐reported sleep problems (0‐100 scale) Higher scores indicate higher sleep problem levels Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 8 studies · 4547 participants | Low Downgraded: indirectness, publication bias |
Self‐reported health‐related quality of life (0‐100 scale) Higher scores indicate higher burden of disease (lower quality of life) Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 14 studies · 6861 participants | Low Downgraded: indirectness, publication bias |
Tolerability (withdrawal due to adverse events) Serotonin noradrenaline reuptake inhibitors vs placebo | RD 0.07 [0.04, 0.1] | 15 studies · 7029 participants | Low Downgraded: indirectness, publication bias |
Safety (serious adverse events) Serotonin noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 13 studies · 6732 participants | Very low Downgraded: imprecision, indirectness, publication bias |